Ranbaxy enters into licensing pact with EPIRUS Switzerland

Ranbaxy Laboratories today inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab prescribed to treat rheumatoid arthritis (RA).

EPIRUS Switzerland GmbH is a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, Inc.

The product will be introduced in India and other Emerging Markets, the company said in a statement.

At present, there is no biosimilar of Infliximab approved in India, it said.

Under the terms of the agreement, EPIRUS will develop and supply the product; and upon regulatory approval, Ranbaxy will market the same in India and other emerging markets.

Commenting on the partnership, Sanjeev I Dani, Executive Vice President & Head, Global Strategy, Ranbaxy, said, "We will utilise our strong front-end capabilities in making this product available in India and other parts of the world."

Amit Munshi, President and CEO of EPIRUS said: "We are very pleased to work with Ranbaxy to register and commercialise this important medicine. Ranbaxy has the right focus and infrastructure in these markets to effectively bring this product to the market."


  • With IT firms pursuing independent business models, Infosys is no longer a bellwether

    The earnings season kicked off on Monday with technology major Infosys announcing its second quarter results that were more or less on expected lines


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Taslima Nasreen

Saudi Arabia will never be shamed

The health minister of Saudi Arabia Khalid Al-Falih has purportedlysaid ...

Kuruvilla Pandikattu

Our mood effects our walking style

Our mood can affect how we walk. We walk lazy ...

Dharmendra Khandal

Use technology wisely to save earth's treasures

Wildlife biologists are certainly getting inspired by our armed forces’ ...


William D. Green

Chairman & CEO, Accenture